Acknowledgments
We are grateful to Maite Martín and Mónica Pérez for their outstanding technical assistance and to the Mycobacteria Section of the National Veterinary Services Laboratories (US Department of Agriculture, Animal and Plant Health Inspection Service) for the sequencing service and technical support.

This work was supported by the Department of Agriculture, Livestock Fisheries and Food of the Government of Catalonia and by the Spanish Ministry of Agriculture, Fisheries and Food. The Institute of Agrifood Research and Technology is supported by Centres de Recerca de Catalunya Programme/Generalitat de Catalunya.

About the Author
Dr. Pérez de Val is a researcher at the Institut de Recerca i Tecnologia Agroalimentaries-Centre de Recerca en Sanitat Animal, Barcelona, Spain, where he conducts research on control and surveillance of TB.

References
1. Samper S, Iglesias MJ, Rabanaque MJ, Gómez LI, Lafoz MC, Jiménez MS, et al.; Spanish Working Group on MDR-TB. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol. 2005;43:1220–7. https://doi.org/10.1128/JCM.43.3.1220-1227.2005
2. Rodríguez E, Sánchez LP, Pérez S, Herrera L, Jiménez MS, Samper S, et al. Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain, 2004-2007. Int J Tuberc Lung Dis. 2009;13:1536–41.
3. Muñoz Mendoza M, Juan L, Menéndez S, Ocampo A, Mourelo J, Sáez JL, et al. Tuberculosis due to Mycobacterium bovis and Mycobacterium caprae in sheep. Vet J. 2012;191:267–9. https://doi.org/10.1016/j.tvjl.2011.05.006
4. Vidal E, Grasa M, Perálvarez T, Martín M, Mercader I, Pérez de Val B. Transmission of tuberculosis caused by Mycobacterium caprae between dairy sheep and goats. Small Rumin Res. 2018;158:22–5. https://doi.org/10.1016/j.smallrumres.2017.11.010
5. Balseiro A, Altuzarra R, Vidal E, Moll X, Espada Y, Sevilla IA, et al. Assessment of BCG and inactivated Mycobacterium bovis vaccines in an experimental tuberculosis infection model in sheep. PLoS One. 2017;12:e0180546. https://doi.org/10.1371/journal.pone.0180546
6. Scorpio A, Collins D, Whipple D, Cave D, Bates J, Zhang Y. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol. 1997;35:106–10. https://doi.org/10.1128/JCM.35.1.106-110.1997
7. Romero B, Aranz A, Bezos J, Alvarez J, de Juan L, Tariq Javed M, et al. Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals. Tuberculosis (Edinb). 2007;87:565–71. https://doi.org/10.1016/j.tube.2007.08.004
8. Nebreda-Mayoral T, Brezmes-Valdivieso MF, Gutiérrez-Zúñiarrue N, García-de Cruz S, Labayru-Echeverría C, López-Medrano R, et al. Human Mycobacterium bovis infection in Castile and León (Spain), 2006-2015 [in Spanish]. Enferm Infecc Microbiol Clin. 2019;37:19–24. https://doi.org/10.1016/j.eimc.2017.11.018
9. Samper S, Martín C, Pinedo A, Rivero A, Blázquez J, Baquero F, et al. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. AIDS. 1997;11:1237–42. https://doi.org/10.1097/00002030-199710000-00006
10. Menzies D, Benedetti A, Paydar A, Royce S, Madhubkar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000150. https://doi.org/10.1371/journal.pmed.1000150

Address for correspondence: Bernat Pérez de Val, Institut de Recerca i Tecnologia Agroalimentaries-Centre de Recerca en Sanitat Animal Edifici CreSA. Campus of the Autonomous University of Barcelona, 08193-Bellaterra, Barcelona, Spain; email: bernat.perez@irta.cat

Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan
Takahisa Fujino, Hidetoshi Nomoto, Satoshi Kutsuna, Mugen Ujiie, Tetsuya Suzuki, Rubuna Sato, Tsuguto Fujimoto, Makoto Kuroda, Takaji Wakita, Norio Ohmagari

Author affiliations: National Center for Global Health and Medicine, Tokyo, Japan (T. Fujino, H. Nomoto, S. Kutsuna, M. Ujiie, T. Suzuki, R. Sato, N. Ohmagari); Tohoku University, Miyagi, Japan (H. Nomoto, T. Suzuki, N. Ohmagari); National Institute of Infectious Diseases, Tokyo (T. Fujimoto, M. Kuroda, T. Wakita)

DOI: https://doi.org/10.3201/eid2704.210138

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with higher transmission potential have been emerging globally, including SARS-CoV-2 variants from the United Kingdom and South Africa. We report 4 travelers from Brazil to Japan in January 2021 infected with a novel SARS-CoV-2 variant with an additional set of mutations.
Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1), has wreaked havoc worldwide. SARS-CoV-2 causes severe respiratory failure, often rapidly in susceptible patients. Moreover, new variants with estimated higher transmission rates have begun circulating globally, such as Variant of Concern 202012/01 (VOC-202012/01) from the United Kingdom and variant 501Y.V2 from South Africa (2). The virulence, reinfec tion potential, antibody response to, and efficacy of vaccines against these strains, are still unknown, posing a risk for future pandemics. We detected a previously unreported SARS-CoV-2 variant strain in a family arriving in Japan from Brazil.

On January 2, 2021, a healthy man in his 40s arrived at Haneda Airport, Tokyo, Japan, from Amazonas state in Brazil via Istanbul, Turkey. At the airport quarantine station, he and the 3 family members traveling with him tested positive for SARS-CoV-2 by quantitative real-time reverse transcription PCR. All 4 were asymptomatic and were accommodated in a government-designated quarantine facility to wait out the required 14-day quarantine.

On day 2 of their visit, a fever of 37.6°C developed in the man; on day 4, the man had a cough. On day 3, oxygen therapy was not needed, and his general condition improved marginally. On day 3, oxygen therapy was not needed, blood tests showed a decrease in C-reactive protein levels, and no adverse side effects of treatment were observed. He continued treatment with 100 mg/d remdesivir and unfractionated heparin until day 5 of admission and dexamethasone until day 7, during which time we observed no flare-up of symptoms.

We subjected the SARS-CoV-2 detected in the case-patient and in his family to whole-genome sequencing. Phylogenetic analysis suggested a novel variant (GISAID [https://www.gisaid.org] reference no. EPI_ISL_792681) belonging to pangolin lineage P.1 with 12 nonsynonymous mutations including K417T, E484K, and N501Y in the receptor-binding domain of the spike protein (N.R. Faria et al., unpub data, https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586). In addition, the variant strain we detected in the travelers had the N501Y mutation in the receptor-binding site of the spike protein, as noted in VOC-202012/01 and 501Y.V2, and the E484K mutation, similar to that noted in the 501Y strain.

We did not observe any remarkable difference in the clinical course of this case-patient compared with COVID-19 cases caused by other known SARS-CoV-2 strains. According to multiple modeling analyses, the new VOC-202012/01 variant could be more infectious than previous strains and might have <70% increased transmissibility (3–5). Moreover, PCR testing and genomic analysis for this strain suggested an increased viral load in VOC-202012/01 variant. Another strain, 501Y.V2 from South Africa, also has been suggested to have increased transmissibility (H. Tegally et al., unpub data, https://doi.org/10.1101/2020.12.21.20248640). However, to date, no definitive evidence has shown that either VOC-202012/01 or 501Y.V2 are associated with more severe COVID-19 cases.

The symptoms in this patient were relatively mild, although short-term oxygen administration was necessary. Onset of pneumonia a week after the onset of disease also followed the conventional clinical course. However, because the patient was young and had no underlying conditions, this case cannot be generalized.

In conclusion, we identified a novel variant strain of SARS-CoV-2 in 4 travelers from Brazil. Variant strains are appearing across the world now, and quarantine systems need to be strengthened. We hope to elucidate the infectivity, pathogenicity, and relationship of SARS-CoV-2 variants to vaccines while continuing to take conventional precautions against novel variant strains.
Acknowledgments
We thank Tsuyoshi Sekizuka, Kentaro Itohawa, Masanori Hashino, Nozomu Hanoka, Nobuo Koizumi, and Tsuguto Fujimoto for assistance with PCR testing and whole-genome sequencing, and we thank the clinical staff at the National Center for Global Health and Medicine for their dedicated clinical practice and patient care.

This work was supported by the Health, Labor, and Welfare Policy Research Grants, Research on Emerging and Re-emerging Infectious Diseases and Immunization (grant no. 20HA1006).

About the Author
Dr. Fujino is a physician at the National Center for Global Health and Medicine in Shinjuku-ku, Tokyo, Japan. His main research interest is hematology.

References
1. World Health Organization. Coronavirus disease (COVID-19) situation reports. Weekly epidemiological update—19 January 2021 [cited 2021 Jan 21]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2. World Health Organization. SARS-CoV-2 variant [cited 2021 Jan 21]. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/
3. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom; December 20, 2020 [cited 2021 Jan 21]. https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spikeprotein-mutations-United-Kingdom.pdf
4. The New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01. 2020 Dec 18 [cited 2021 Jan 21]. https://app.box.com/s/3lkbxpqixkg4mv640dpvg978ixjtf/file/756963730457
5. The New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG/SPR-K Extraordinary meeting on SARS-CoV-2 variant of concern 202012/01 (variant B.1.1.7). Note of meeting 2020 Dec 21 [cited 2021 Jan 21]. https://app.box.com/s/3lkbxpqixkg4mv640dpvg978ixjtf/file/756964987830

We report new cases of Rocky Mountain spotted fever in patients from Kinkantu, Ngäbe-Bugle indigenous comarca, Panama. We isolated Rickettsia rickettsii in cell culture after intraperitoneal inoculation of guinea pigs with tissues from a deceased patient. Our results indicate that Rocky Mountain spotted fever is emerging in this region.

Isolation of Rickettsia rickettsii in Rocky Mountain Spotted Fever Outbreak, Panama
Yamitzel Zaldívar, Michelle Hernández, Lillian Domínguez, Liseth Saénz, Santiago Montilla, Maria E. Barnett de Antinori, Felipe S. Krawczak, Sergio Bermúdez

Author affiliations: Gorgas Memorial Institute for Health Research, Panama City, Panama (Y. Zaldívar, M. Hernández, L. Domínguez, L. Saénz, S. Montilla, M.E.B. de Antinori, S. Bermúdez); School of Veterinary Medicine and Animal Science, Federal University of Goiás–UFG, Goiânia, Brazil (F.S. Krawczak); Coiba Scientific Station, Panama City (S. Bermúdez)

DOI: https://doi.org/10.3201/eid2704.201606

Rocky Mountain spotted fever (RMSF) causes severe cases of rickettsiosis and is considered a principal tickborne pathogen in the Americas (1). Clinical suspicion is crucial for timely therapy with doxycycline to prevent severe illness and death (1). In Panama, 5 cases of RMSF were reported during 1950–1953, of which 2 were fatal; since 2004, a total of 19 new cases have been reported in Panama, with 13 fatal cases (2). We report new cases of RMSF from Piedra Roja, a rural village of Kankintu, Ngäbe-Bugle indigenous comarca, located at 750 m above sea level in the western mountainous region of Panama without road access.

In February 2019, a total of 7 persons 3–20 years of age from a family cluster had a clinical picture characterized by temperatures of 39°C–41°C (100%), generalized exanthema (100%), diarrhea and vomiting (86%), headaches (71%), severe dehydration (57%), abdominal pain (43%), and hepatomegaly and jaundice (29%). The patients reported no history of recent tick bites or attachment; according to each patient, the duration of symptoms varied from 9 to 11 days. Of these 7 patients, 2 recovered after treatment with doxycycline, 1 recovered without treatment with doxycycline, and 4 died.

We diagnosed rickettsiosis by PCR on blood and samples of spleen, liver, brain and lung, using the